9-20-09

IA



Docket No.: 04577/0200726-US0

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Xiaobing Wu et al.

Application No.: 10/750,620

o.: 10/750,620 Confirmation No.:

Filed: December 30, 2003

Art Unit: N/A

For: METHOD TO PREVENT TRANSPLANT

REJECTION BY STABLE EXPRESSION OF

HEME OXYGENASE-1

Examiner: Not Yet Assigned

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each document on the PTO/SB/08 is attached.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: September 17, 2004

Respectfully submitted

Kristin E. Behrendt

Registration No.: 45,599

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 753-6237 (Fax)

Attorneys/Agents For Applicant



Aþplication No. (if known): 10/750,620

Attorney Docket No.: 04577/0200726-US0

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. 7 6 9 7 5 9 5 - us

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	September 17, 2004
	Date

12 Davis	
Signature	
DDAVIS	
Typed or printed name of person signing Certificate	

Typed or printed name of person signing Certificate

Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement (2 pages)

PTO/SB/08 (3 pages) and Thirty two (32) documents

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Su	bstitute for form 1449A/B/P	τO		Complete if Known		
"				Application Number	10/750,620	
	NFORMATIO	N DI	SCLOSURE	Filing Date	December 30, 2003	
5	TATEMENT	BY A	APPLICANT	First Named Inventor	Xiaobing Wu	
`				Art Unit	N/A	
İ	(Use as many st	reets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	3	Attorney Docket Number	04577/0200726-US0	

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ°	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1.	Pascual M, et al., Strategies To Improve Long-Term Outcomes After Renal Transplantation. N Engl J Med. (2002) 346, 580-90.	
	2.	Tilney NL, et al., Chronic Rejection. Transplant Proc (1998) 30, 1590-1594.	
	3.	Libby P and Pober JS, Chronic Rejection. Immunity (2001) 14, 387-397.	
= = .	4.	Schuller DJ, et al., Crystal Structure Of Human Heme Oxygenase-1. Nat. Structural Biology (1999) 6, 860-867.	
	5.	Maines MD, The Hemc Oxygnase System: A Regulator Of Second Messenger Gases. Annu. Rev. Pharmacol. Toxicol. (1997) 37, 517-554.	
	6.	Otterbein LE, et al., Carbon Monoxide Has Anti-Inflammatory Effects Involving The Mitogen-Activated Protein Kinase Pathway. Nat. Med. (2000) 6, 422-428.	
	7.	Minamino T, et al., Targeted Expression Of Heme Oxygnase-1 Prevents The Pulmonary Inflammatory And Vascular Responses To Hypoxia. Proc. Natl. Acad. Sci. USA (2001) 98, 8798-8803.	
	8.	Amersi F, et al., Upregulation Of Heme Oxygenase-1 Protects Genetically Fat Zucker Rat Livers From Ischemis/Reperfusion Injury. J. Clin. Invest. (1999) 104, 1631-1639.	
	9.	Yet SF, et al., Cardiac-Specific Expression Of Heme Oxygenase-1 Protects Against Ischemia	İ

Examiner Date Signature Considered			
Signature Considered	Examiner	Date	
	Signature	Considered	

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	ostitute for form 1449A/B/PT	0		Complete if Known		
		•		Application Number	10/750,620	
11	NFORMATION	N DI	SCLOSURE	Filing Date	December 30, 2003	
S	TATEMENT I	BY /	APPLICANT	First Named Inventor	Xiaobing Wu	
			-	Art Unit	N/A	
	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	3	Attorney Docket Number	04577/0200726-US0	

	And Reperfusion Injury In Transgenic Mice. Circ. Res. (2001) 89, 168-173.
10.	Soares MP, et al., Expression Of Heme Oxygenase-1 Can Determine Cardiac Xenograft Survival. Nat. Med. (1998) 4, 1073-1077.
11.	Debruyne LA, et al.,. Gene Transfer Of Immunomodulatory Peptides Correlates With Heme Oxygenase-1 Induction And Enhanced Allograft Survival. Transplantation (2000) 69, 120-128.
12.	Hancock WW, et al., Antibody-Induced Transplant Arteriosclerosis Is Prevented By Graft Expression Of Anti-Oxidant And Anti-Apoptosic Genes. Nat. Med. (1998) 4, 1392-1396.
13.	Zhijian WU, et al., Generation Of A Recombinant Herpes Simplex Virus Which Can Provide Packaging Function For Recombinant Adeno-Associated Virus. Chinese Science Bulletin (1999) 44, 715-718.
14.	Xiobing WU, et al., A Novel Method For Purification Of Recombinant Adeno-Associated Virus Vectors On A Large Scale. Chinese Science Bulletin (2001) 46, 484-489.
15.	Samulski RJ, et al., Helper-Free Stocks Of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression. J. Virol. (1989) 63, 3822-3828.
16.	Demetris AJ, et al., Analysis of Chronic Rejection and Obliterative Arteriopathy Am. J. Pathol. (1997) 150, 563-578.
17.	Border WA and Nobel NA, <i>Transforming Growth Factor-β In Tissue Fibrosis</i> . N. Engl. J. Med. (1994) 331, 1286-1292.
18.	Kaplitt MG, et al., Long-Term Gene Expression And Phenotypic Correction Using Adeno Associated Virus Vectors In The Mammalian Brain. Nat. Genet. (1994) 8, 148-154.
19.	Owens RA, et al., Second Generation Adeno-Associated Virus Type 2-Based Gene Therapy Systems With The Potential For Preferential Integration Into AAVS1. Curr. Gene Ther. (2002) 2, 145-159
20.	Brouard S, et al., Carbon Monoxide Generated By Heme Oxygenase 1 Supresses Endothelial Cell Apoptosis. J. Exp. Med. (2000) 192, 1015-1025.
21.	Lee TS and Chau LY, Heme Oxygnnse-1 Mediated The Anti-Inflammatory Effect Of Interleukin-10 In Mice. Nat. Med. (2002) 8, 240-246.
22.	Duckers HJ, et al., Heme Oxygenase-1 Protects Against Vascular Constriction and Proliferation. Nature Medicine (2001) 7, 693-698.
23.	Peyton KJ, et al., Heme Oxygenase-1 Derived Carbon Monoxide Is An Autocrine Inhibitor Of Vascular Smooth Muscle Cell Growth. Blood (2002) 99, 4443-4448.

Examiner	Date
Signature	Considered

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/B/PT	0			Complete if Known
		_		Application Number	10/750,620
IN	<b>IFORMATION</b>	I DI	SCLOSURE	Filing Date	December 30, 2003
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Xiaobing Wu
				Art Unit	N/A
	(Use as many she	eets as	necessary)	Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	04577/0200726-US0

24.	Tulis DA, et al., Adenovirus-Mediated Heme Oxygenase-1 Gene Delivery Inhibits Injury-Induced Vascular Neointima Formation. Circulation (2001) 104, 2710-2715.
25.	Liu X, et al., Adenovirus-Mediated Heme Oxygenase-1 Gene Expression Stimulates Apoptosis In Vascular Smooth Muscle Cells. Circulation (2002) 105, 79-84.
26.	Waltenberger J, et al., Induction Of Transforming Growth Factor-β During Cardiac Allograft Rejection. J. Immunol. (1993) 151, 1147-1157.
27.	Little DM, et al., Does Transforming Growth Factor β 1 Play A Role In The Pathogenesis Of Chronic Allograft Rejection? Transpl. Int. (1999) 12, 393-401.
 28.	Pascual M, et al., Chronic Rejection And Chronic Cyclosporin Toxicity In Renal Allografts. Immunol. Today (1998) 19, 514-519.
 29.	Fujita T, et al., Paradoxical Rescue From Ischemic Lung Injury By Inhaled Carbon Monoxide Driven By Derepression Of Fibrinolysis. Nat. Med. (2001) 7, 598-604
30.	Shibahara S, et al., Cloning And Expression Of cDNA For Rat Heme Oxygenase. Proc. Natl. Acad. Sci. USA (1985) 82:7865-7869.
31.	Ono K and Lindsay ES, Improved Technique Of Heart Transplantation In Rats. J. Thorac. Cardiovasc. Surg. (1969) 57:225.
 32.	Tsui TY, et al., Prevention Of Chronic Deterioration Of Heart Allograft By Recombinant Adeno- Associated Virus-Mediated Heme Oxygenase-1 Gene Transfer. Circulation (2002) 2623-2629.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	l
Signature	Considered	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.